thelancet.com
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised tria...
This randomised trial did not show a difference in overall survival between neoadjuvant
FOLFIRINOX and neoadjuvant gemcitabine-based chemoradiotherapy in patients with resectable
or borderline resecta...